ZD1839 (‘Iressa’) provides clinically significant antitumor activity and improves disease-related symptoms in pretreated patients with advanced non-small-cell lung cancer (NSCLC): results of two Phase II trials (IDEAL 1 and IDEAL 2)

• Book ID: 117659519
• Publisher: Elsevier Science
• Year: 2002
• Tongue: English
• Weight: 277 KB
• Volume: 38
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(02)80827-9